In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Making The Most Of A Maturing Myriad Genetics

Executive Summary

Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.


Related Content

Myriad Builds Case For Personalized Rheumatoid Arthritis Drugs
Myriad Enters Companion Diagnostics Field With An FDA First
FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions
Option Deal Structure Works For Myriad As It Moves To Buy Crescendo
Myriad Seeks To Diversify While Remaining Aggressive On BRCA Testing Market
Myriad Gets Mixed Decision in Supreme Court; Biotech Industry Fears Fallout
Genomics Through The Lens Of Precompetitive Data Sharing
The Alzheimer's Divide
Genomics and Proteomics Forays into Psychiatric Illness
Genentech and Inotek Pair Up in PARP Inhibition


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts